Panel Intelligence, LLC, April 2008
Vytorin and Zetia use
Inclusion Criteria and Respondent Demographics:
- US-based
- 2 to 30 years of experience post-training
- Minimum of 75% professional time spent in clinical practice
- Writes at least
Datamonitor, Nov 2011, Pages: 37
other than LDL-C. The availability of generics of not only statins but Niaspan, Zetia and Tricor will create an environment that will make establishing market share for a premium product more challenging
GenericsWeb, June 2012
Ezetimibe
Ezetimibe indications: Hypercholesterolemia; Sitosterolemia
Ezetimibe innovator: MSD (Zetia, Ezetrol); Schering Plough (Zetia, Ezetrol)
Examples of information found in this online report include
GenericsWeb, June 2012
Ezetimibe
Ezetimibe indications: Hypercholesterolemia; Sitosterolemia
Ezetimibe innovator: MSD (Zetia, Ezetrol); Schering Plough (Zetia, Ezetrol)
Examples of information found in this online report include
Business Insights, April 2007, Pages: 101
Chapter 2 Global launch strategies 30
Summary 30
Introduction 31
Global launch sequence 32
Case study: Zetia (ezetimibe) 34
Global brand strategies 35
Global marketing strategies 37
Reflections and
Datamonitor, March 2009, Pages: 163
growth driver Zetia/Vytorin
CHAPTER 1 ABOUT THIS PROFILE
Executive summary
Quarterly news update
Company introduction
Company sales
Company financials
Key products and competitors
Data sourcing
GlobalData, Nov 2010, Pages: 36
Lomitapide + Zetia
Product Description
Mechanism of Action
R&D Progress
Aegerion Pharmaceuticals, Inc. – Pipeline Analysis
Aegerion Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class
Espicom Business Intelligence Ltd, Nov 2009, Pages: 186
main tools to offset these losses have emerged from its successful joint venture with Schering-Plough, which has seen Vytorin and Zetia come to market. Vytorin in particular is expected to become a major
Global Industry Analysts, Inc., April 2010, Pages: 429
Marketing ZETIA® II-24
5. RECENT INDUSTRY ACTIVITY II-25
Abbott and Solvay Group Enter into Definitive Agreement II-25
Daiichi Sankyo Establishes New Subsidiary II-25
AstraZeneca Introduces Crestor II-25
Decision Resources, Inc., Nov 2008, Pages: 43
-Point Action Agenda
A. U.S. Prescription Trends for Vytorin and Zetia, 2008
Sidebars
Fallout from the ENHANCE Trial, 2008 - 454 Life Sciences
- Abbott Laboratories
- Actelion
- Adnexus Therapeutics
